With circa 30 employees already, LBT continue to actively recruit - two additional roles currently advertised.
Assume they’re either aggressively developing additional APAS Analysis Modules, advancing Early Plate Reading capability or perhaps working on a new capability - industry expansion into Dairy and Pharma has been mentioned in a couple of recent presentations.
Otherwise:
- MRSA is already with the FDA
- VRE already developed and in clinical trial
- Urine already developed and in clinical trial
- AMR early version developed
